Rezulin is a prescription drug manufactured by Parke-Davis/Warner-Lambert and its approved usage is for treatment of type 2 (adult onset) diabetes mellitus in individuals for whom other therapies failed. Type 2 develops when the body no longer responds to insulin. There have been at least 61 deaths from liver failure that have been linked to usage of this drug.

Rezulin was first offered on the market in the United States in January of 1997. In October of 1997, the manufacturer issued a label change warning of adverse liver effects and recommending liver monitoring five (5) times a year. In December of 1997, Parke-Davis issued a letter to physicians calling for a label change which recommended liver monitoring ten (10) times a year. Boxed warnings were added to include additional liver enzyme testing. During this same time period, Rezulin was withdrawn from the market in the United Kingdom. In July of 1998, the label was again changed to recommend liver monitoring eleven (11) times a year. In June of 1999, the FDA limited the drug usage to a select group of patients not well-controlled on other diabetes medication. Finally, on March 21, 2000, the FDA asked the manufacturer to remove this product form the United States market after finding that continued use of Rezulin posed an unacceptable risk of liver toxicity to patients, as compared to two similar drugs that were recently approved. The manufacturer agreed.

If you would like to speak with someone concerning Rezulin, you may discuss your particular situation with an experienced attorney at the law offices of LeBlanc & Waddell by telephone at 800-988-3514, by fax at 225-768-7999, or by contacting us online.

For more information on Rezulin and Liver Disease click here for the Rezulin Legal Alliance "Rezulin Newsletter."